November 2024's Top Picks: Penny Stocks On US Exchanges

In This Article:

As November 2024 comes to a close, the U.S. stock market has been making headlines with the S&P 500 and Dow Jones Industrial Average reaching record highs and posting their largest monthly gains of the year. Amidst this robust market performance, investors are increasingly exploring diverse opportunities, including those offered by penny stocks. While often considered a throwback to earlier trading days, penny stocks represent smaller or newer companies that can offer significant potential when backed by strong financials. In this article, we will explore three such penny stocks on U.S. exchanges that stand out for their financial strength and growth potential.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.802475

$5.83M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$145.67M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.72

$139.43M

★★★★★☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.22

$8.1M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$4.90

$805.62M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.58

$52.14M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.952

$85.62M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.84

$410.03M

★★★★☆☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Adagene

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Adagene Inc. is a clinical-stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancer treatment, with a market cap of $102.27 million.

Operations: Adagene Inc. has not reported any revenue segments.

Market Cap: $102.27M

Adagene Inc., with a market cap of US$102.27 million, is pre-revenue, generating less than US$1 million. The company has a robust cash runway exceeding three years and short-term assets of US$98.8 million surpassing its liabilities, suggesting financial stability despite rising debt levels over five years. Recent data from the SITC 2024 conference highlighted promising therapeutic potential for ADG126 in combination with pembrolizumab for MSS colorectal cancer treatment, showing enhanced efficacy and safety profiles compared to existing therapies. However, Adagene remains unprofitable with earnings projected to decline annually by 10.5% over the next three years.